Hepatitis C Virus Infection in Pregnant Individuals with Opioid Use Disorder and Its Association with Preterm Birth

Aneesha Cheedalla; Marissa Berry; Mahmoud Abdelwahab; Jamie Cowen; Alexandra Stiles; Isabelle Mason; Jonathan R. Honegger; Kara M. Rood

doi:10.1055/a-2413-2306

American Journal of Perinatology, Table of Contents

Am J Perinatol 2025; 42(05): 599-604
DOI: 10.1055/a-2413-2306

Original Article

Hepatitis C Virus Infection in Pregnant Individuals with Opioid Use Disorder and Its Association with Preterm Birth

Authors

Aneesha Cheedalla

¹Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, Ohio
Marissa Berry

¹Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, Ohio
Mahmoud Abdelwahab

¹Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, Ohio

²Division of Maternal-Fetal Medicine, West Virginia University, Morgantown, Ohio
Jamie Cowen

¹Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, Ohio
Alexandra Stiles

¹Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, Ohio
Isabelle Mason

¹Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, Ohio
Jonathan R. Honegger

³Division of Infectious Diseases, Nationwide Children's Hospital, Columbus, Ohio
Kara M. Rood

¹Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, Ohio

Abstract

Objective

Both hepatitis C virus (HCV) and opioid use disorder (OUD) have been associated with higher rates of preterm birth (PTB). It is unknown whether the higher prevalence of HCV in individuals with OUD may contribute to this association. The objective of this study is to evaluate the association between HCV and PTB in pregnant individuals with OUD.

Study Design

We conducted a retrospective cohort of pregnant individuals with OUD who participated in more than three visits in a co-located multidisciplinary program. Inclusion criteria were a diagnosis of OUD, participation in treatment/prenatal care program, and laboratory evaluation of HCV status. The primary exposure was the presence of HCV antibodies, and secondarily, a detectable viral load (viremia). The primary outcome was PTB, which was further classified as spontaneous or iatrogenic. Multivariable logistic regression was used to detect associations while adjusting for race, history of prior PTB, and tobacco use.

Results

A total of 941 individuals were included in the study, 404 with HCV and 537 without. Rates of PTB did not differ between those with compared to those without HCV (20.3 vs. 23.8%, adjusted odds ratio [aOR] = 0.75 [95% confidence interval (CI): 0.53–1.07]). There were similar rates of spontaneous PTB (13.1 vs. 16.2%, aOR = 0.79 [95% CI: 0.43–1.45]) and iatrogenic PTB (7.2 vs. 7.6%, aOR = 1.26 [95% CI: 0.69–2.30]). Comparing those with viremia to those without, there were also similar rates of overall PTB (21.6 vs. 17.9%, aOR = 0.86 [95% CI: 0.52–1.44]), spontaneous PTB (13.3 vs. 12.9%, aOR = 0.97 [95% CI: 0.52–1.87]), and iatrogenic PTB (8.3 vs. 5.0%, aOR = 1.83 [95% CI: 0.76–4.94]).

Conclusion

HCV does not appear to be associated with spontaneous or iatrogenic PTB in pregnant persons with OUD who are engaged in treatment and prenatal care. The role of co-located multidisciplinary prenatal and addiction programs in the association between HCV and PTB warrants further investigation.

Key Points

Hepatitis C antibodies are not associated with PTB in those with OUD.
Hepatitis C viremia is not associated with PTB.
Multidisciplinary treatment programs may contribute to these findings.

Keywords

hepatitis C virus - opioid use disorder - preterm birth

Full Text

References

References
1 Centers for Disease Control and Prevention. 2020 Hepatitis C | Viral Hepatitis Surveillance Report. Published September 14, 2022. Accessed May 22, 2023 at: https://www.cdc.gov/hepatitis/statistics/2020surveillance/hepatitis-c.htm
2 Arditi B, Emont J, Friedman AM, D'Alton ME, Wen T. Deliveries among patients with maternal hepatitis C virus infection in the United States, 2000-2019. Obstet Gynecol 2023; 141 (04) 828-836
3 Holtzman D, Asher AK, Schillie S. The changing epidemiology of hepatitis C virus infection in the United States during the years 2010 to 2018. Am J Public Health 2021; 111 (05) 949-955
4 Rossi RM, Warshak CR. Prevalence of maternal hepatitis C virus infection in Ohio. Obstet Gynecol 2018; 132 (03) 708-716
5 Ahrens KA, Rossen LM, Burgess AR, Palmsten K, Ziller EC. Maternal hepatitis C prevalence and trends by county, US: 2016-2020. Paediatr Perinat Epidemiol 2023; 37 (02) 134-142
6 Piffer S, Mazza A, Dell'Anna L. Serological screening for hepatitis C during pregnancy: Seroprevalence and maternal and neonatal outcomes in 45,000 pregnant women. Eur J Obstet Gynecol Reprod Biol 2020; 254: 195-199
7 Reddick KLB, Jhaveri R, Gandhi M, James AH, Swamy GK. Pregnancy outcomes associated with viral hepatitis. J Viral Hepat 2011; 18 (07) e394-e398
8 Connell LE, Salihu HM, Salemi JL, August EM, Weldeselasse H, Mbah AK. Maternal hepatitis B and hepatitis C carrier status and perinatal outcomes. Liver Int 2011; 31 (08) 1163-1170
9 Rossi RM, Wolfe C, Brokamp R. et al. Reported prevalence of maternal hepatitis C virus infection in the United States. Obstet Gynecol 2020; 135 (02) 387-395
10 American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. Prediction and prevention of spontaneous preterm birth: ACOG Practice Bulletin, Number 234. Obstet Gynecol 2021; 138 (02) e65-e90
11 Huang QT, Huang Q, Zhong M. et al. Chronic hepatitis C virus infection is associated with increased risk of preterm birth: a meta-analysis of observational studies. J Viral Hepat 2015; 22 (12) 1033-1042
12 Shen GF, Ge CH, Shen W, Liu YH, Huang XY. Association between hepatitis C infection during pregnancy with maternal and neonatal outcomes: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2023; 27 (08) 3475-3488
13 Kushner T, Djerboua M, Biondi MJ, Feld JJ, Terrault N, Flemming JA. Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission. J Hepatol 2022; 77 (05) 1256-1264
14 American College of Obstetrics and Gynecology. Committee Opinion No. 711: Opioid use and opioid use disorder in pregnancy. Obstet Gynecol 2017; 130 (02) e81-e94
15 Amercian Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. 2013
16 Abdelwahab M, Petrich M, Wang H, Walker E, Cleary EM, Rood KM. Risk factors for preterm birth among gravid individuals receiving buprenorphine for opioid use disorder. Am J Obstet Gynecol MFM 2022; 4 (03) 100582
17 Stokkeland K, Ludvigsson JF, Hultcrantz R. et al. Pregnancy outcome in more than 5000 births to women with viral hepatitis: a population-based cohort study in Sweden. Eur J Epidemiol 2017; 32 (07) 617-625
18 Krans EE, Kim JY, Chen Q. et al. Outcomes associated with the use of medications for opioid use disorder during pregnancy. Addiction 2021; 116 (12) 3504-3514
19 Baer RJ, Chambers CD, Ryckman KK, Oltman SP, Rand L, Jelliffe-Pawlowski LL. Risk of preterm and early term birth by maternal drug use. J Perinatol 2019; 39 (02) 286-294
20 Suarez EA, Huybrechts KF, Straub L. et al. Buprenorphine versus methadone for opioid use disorder in pregnancy. N Engl J Med 2022; 387 (22) 2033-2044
21 Berkley EMF, Leslie KK, Arora S, Qualls C, Dunkelberg JC. Chronic hepatitis C in pregnancy. Obstet Gynecol 2008; 112 (2 Pt 1): 304-310
22 Pergam SA, Wang CC, Gardella CM, Sandison TG, Phipps WT, Hawes SE. Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort. Am J Obstet Gynecol 2008; 199 (01) 38.e1-38.e9
23 Hood RB, Miller WC, Shoben A, Harris RE, Norris AH. Maternal hepatitis C virus infection and adverse newborn outcomes in the US. Matern Child Health J 2023; 27 (08) 1343-1351
24 Beydoun H, Saftlas AF. Physical and mental health outcomes of prenatal maternal stress in human and animal studies: a review of recent evidence. Paediatr Perinat Epidemiol 2008; 22 (05) 438-466
25 Dole N, Savitz DA, Hertz-Picciotto I, Siega-Riz AM, McMahon MJ, Buekens P. Maternal stress and preterm birth. Am J Epidemiol 2003; 157 (01) 14-24
26 Weber KA, Carmichael SL, Yang W, Tinker SC, Shaw GM. National Birth Defects Prevention Study. Periconceptional stressors and social support and risk for adverse birth outcomes. BMC Pregnancy Childbirth 2020; 20 (01) 487
27 Foster GR, Irving WL, Cheung MCM. et al; HCV Research, UK. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016; 64 (06) 1224-1231
28 Fogel RS, Chappell CA, Hepatitis C. Hepatitis C virus in pregnancy: an opportunity to test and treat. Obstet Gynecol Clin North Am 2023; 50 (02) 363-373